Even if tumors initially lack CTLs, TKIs including regorafenib have the ability to induce CTL infiltration and function by reducing immunosuppressive cells or by normalizing the HCC vasculature (6, 7), resulting in the secretion of IFNγ. This evidence concerns the gene IFNG and hepatocellular carcinoma.